Evidence map›Paper›PMID 31052505›Full record

ArticleInternational journal of molecular sciences2019

Polysome Profiling of a Human Glioblastoma Reveals Intratumoral Heterogeneity.

Fernanda Cristina Sulla Lupinacci, Hellen Kuasne, Martin Roffé, Julia Avian Vassalakis, Fernanda Ferreira da Silva, Tiago Góss Santos, Victor Piana Andrade, Paulo Sanematsu, Vilma Regina Martins, Silvia Regina Rogatto and 1 more

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 2 countries.

Fernanda Cristina Sulla LupinacciInternational Research Center, A.C.Camargo Cancer Center, National Institute of Science and Technology in Oncogenomics, São Paulo 01509-010, Brazil. flupinacci@accamargo.org.br.
Hellen KuasneInternational Research Center, A.C.Camargo Cancer Center, National Institute of Science and Technology in Oncogenomics, São Paulo 01509-010, Brazil. khellenk@yahoo.com.br.
Martin RofféInternational Research Center, A.C.Camargo Cancer Center, National Institute of Science and Technology in Oncogenomics, São Paulo 01509-010, Brazil. mroffe@accamargo.org.br.ORCID 0000-0001-7247-3067
Julia Avian VassalakisInternational Research Center, A.C.Camargo Cancer Center, National Institute of Science and Technology in Oncogenomics, São Paulo 01509-010, Brazil. julia.vassalakis@accamargo.org.br.
Fernanda Ferreira da SilvaInternational Research Center, A.C.Camargo Cancer Center, National Institute of Science and Technology in Oncogenomics, São Paulo 01509-010, Brazil. fsilva@accamargo.org.br.
Tiago Góss SantosInternational Research Center, A.C.Camargo Cancer Center, National Institute of Science and Technology in Oncogenomics, São Paulo 01509-010, Brazil. tsantos@accamargo.org.br.ORCID 0000-0001-6641-7413
Victor Piana AndradePathology Department, A.C.Camargo Cancer Center, National Institute of Science and Technology in Oncogenomics, São Paulo 01509-010, Brazil. victor.andrade@accamargo.org.br.
Paulo SanematsuNeurosurgery Department, A.C.Camargo Cancer Center, National Institute of Science and Technology in Oncogenomics, São Paulo 01509-010, Brazil. psanematsu@yahoo.com.br.
Vilma Regina MartinsInternational Research Center, A.C.Camargo Cancer Center, National Institute of Science and Technology in Oncogenomics, São Paulo 01509-010, Brazil. vmartins@accamargo.org.br.
Silvia Regina RogattoVejle Hospital, Institute of Regional Health Research, University of Southern, 5230 Odense, Denmark. silvia.regina.rogatto@rsyd.dk.
Glaucia Noeli Maroso HajjInternational Research Center, A.C.Camargo Cancer Center, National Institute of Science and Technology in Oncogenomics, São Paulo 01509-010, Brazil. ghajj@accamargo.org.br.ORCID 0000-0003-2342-7384
AC Camargo Hospital · BRUniversity of Southern Denmark · DK

Funding

Fundação de Amparo à Pesquisa do Estado de São Paulo 2015/15451-3Fundação de Amparo à Pesquisa do Estado de São Paulo 2018/17796-6
6 · The paper itself

Abstract

Glioblastoma (GBM) is one of the most aggressive cancers, with median survival of less than 2 years. Despite of considerable advance in molecular classification of GBMs, no improvements in therapy have been described. The scenario is further complicated by tumor heterogeneity and the relationship among genetic, transcriptional and functional findings. Classically, gene expression has been evaluated by steady-state mRNA, however, this does not take translational control into consideration, which contributes considerably to the composition of the proteome. In this study, we evaluated the transcriptomic and translatomic signature of a GBM obtained from a single patient focusing in tumor heterogeneity. In a sampling of eight fragments, we investigated the translation rates, mTORC1 and ERK1/2 pathways and identified both total and polysome associated mRNAs. An increased translation rate was observed in fragments with high-grade histological features. High-grade histology was also associated with the expression of genes related to extracellular matrix (ECM) and angiogenesis, in both transcriptomes and translatomes. However, genes associated with epithelial to mesenchymal transition and stress response, were observed only in translatomes from high-grade fragments. Overall, our results demonstrate that isolation of translated mRNA can be used to identify biomarkers and reveal previously unrecognized determinants of heterogeneity in GBMs.

Indexed as

Gene Expression ProfilingGene Expression Regulation, NeoplasticCell Line, TumorCentral Nervous System NeoplasmsExtracellular Signal-Regulated MAP KinasesFemaleGlioblastomaHumansMechanistic Target of Rapamycin Complex 1Middle AgedProtein BiosynthesisRNA, MessengerExtracellular Signal-Regulated MAP KinasesMechanistic Target of Rapamycin Complex 1RNA, MessengerglioblastomamTORC1polysometranslation controltranslatometumor heterogeneity

Identifiers

PMID31052505
PMCPMC6539516
OpenAlexW2943746964

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.